Alchemab Therapeutics among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK

23rd June 2020 in Portfolio News

Author: Tony Quested

Publication: Business Weekly

Illumina unveils the first global genomics accelerator cohort and Alchemab Therapeutics, an SV7 Impact Medicine Fund portfolio company, is among the three companies that comprise this funding cycle of Illumina Accelerator Cambridge UK.

View the article

PROUD SIGNATORIES

We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.